Stoke Therapeutics, Inc.
NASDAQ:STOK
13.27 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Stoke Therapeutics, Inc. |
Symbool | STOK |
Munteenheid | USD |
Prijs | 13.27 |
Beurswaarde | 698,636,306 |
Dividendpercentage | 0% |
52-weken bereik | 3.77 - 17.58 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Edward M. Kaye M.D., Ph.D. |
Website | https://www.stoketherapeutics.com |
An error occurred while fetching data.
Over Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)